Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.80), $0.21 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $15.41 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.